Passage Bio To Cut Workforce, Prioritize R&D Programs To Reduce Operating Expenses

Vandana Singh
1 min read
0
In this article:

Passage Bio Inc (NASDAQ: PASG) will reduce its workforce by approximately 13% and prioritize its R&D programs in partnership with the University of Pennsylvania's Gene Therapy Program (GTP).

  • The Company will continue to focus on advancing its three lead clinical programs for GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia (FTD).

  • In conjunction with the headcount reduction, Eliseo Salinas, chief research and development officer, will retire and depart from the Company effective March 18.

  • Mark Forman, chief medical officer, will continue to lead the execution of the ongoing clinical trials.

  • Passage Bio will dose the first patient in Phase 1/2 of FTD-GRN in early 2022.

  • It will submit an Investigational New Drug Application for the Phase 1/2 program for PBML04 (metachromatic leukodystrophy) in mid-2022.

  • The Company will present interim safety and biomarker data for Cohorts 2 (late infantile, high dose) and 3 (early infantile, low dose) for the Imagine-1 clinical trial for GM1 in 2H 2022.

  • Interim safety and biomarker data for Cohort 1 for the GALax-C clinical trial for Krabbe disease will be presented by the end of 2022.

  • The cash balance of $315.8 million can provide a cash runway into Q2 2024 versus year-end 2023.

  • Price Action: PASG shares are trading at $2.81 during the market session on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories